Trevi Therapeutics Stock Price, News & Analysis

Trevi Therapeutics (NASDAQ: TRVI) has presented additional analyses from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) for refractory chronic cough (RCC). The trial met its primary endpoint with a 67% reduction in 24-hour cough frequency from baseline and 57% on a placebo-adjusted basis (p<0.0001). Key findings include:

• Statistically significant responder analyses across all doses at 30%, 50%, and 75% thresholds
• Significant improvement in Leicester Cough Questionnaire at Day 21
• Adverse events were more common during initial exposure (27mg BID) but decreased over time
• Most discontinuations occurred in first two weeks due to CNS and GI-related adverse events

The company awaits Phase 2b trial results in IPF patients with chronic cough to determine future development strategy.

Trevi Therapeutics (NASDAQ: TRVI) reported Q1 2025 financial results and key developments for its drug candidate Haduvio. The company announced positive Phase 2a RIVER trial results showing a significant 67% reduction in 24-hour cough frequency from baseline in refractory chronic cough patients. The Phase 2b CORAL trial for IPF patients with chronic cough completed enrollment and last patient visit, with topline results expected in Q2 2025. Financially, Trevi ended Q1 with $103.3 million in cash, providing runway into Q4 2026. The company reported R&D expenses of $7.8 million (down from $8.8 million in Q1 2024) and G&A expenses of $3.7 million (up from $3.1 million), resulting in a net loss of $10.3 million compared to $10.9 million in the same period last year.

Trevi Therapeutics (NASDAQ: TRVI) has scheduled its Q1 2025 financial results and corporate update conference call for May 8, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), will host the event via conference call and live audio webcast. Investors can join by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website and archived for 30 days afterward.

Trevi Therapeutics (Nasdaq: TRVI), developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced its participation in three major investor conferences this April 2025.

The company will present at the following events:

• 24th Annual Needham Virtual Healthcare Conference (April 7-10) with a corporate presentation on April 7 at 11:00-11:40 a.m. ET
• Jones Healthcare and Technology Innovation Conference (April 8-9) in Las Vegas, with a presentation on April 9 at 11:00-11:20 a.m. PT
• Piper Sandler Spring Biopharma Symposium (April 16-17) in Boston

Trevi Therapeutics (NASDAQ: TRVI) reported significant progress in its clinical trials for Haduvio, a therapy for chronic cough conditions. The company announced positive topline data from Phase 2a RIVER trial showing a 57% placebo-adjusted reduction in 24-hour cough frequency for refractory chronic cough patients.

Key developments include completed enrollment in the Phase 2b CORAL trial for IPF chronic cough patients, with topline data expected in Q2 2025, and positive sample size re-estimation outcome requiring no changes to the study. The company also reported positive results from its Human Abuse Potential study.

Financial highlights for Q4 2024:

• Cash position: $107.6 million, with runway into H2 2026
• R&D expenses: $9.3 million (up from $6.5M in Q4 2023)
• Net loss: $11.4 million (compared to $7.8M in Q4 2023)

Trevi Therapeutics (NASDAQ: TRVI) has scheduled its fourth quarter and year-end 2024 financial results announcement and corporate update for March 18, 2025, at 4:30 p.m. ET. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), will host a conference call and live audio webcast.

Participants can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). The webcast will be available through the 'Investors & News' section on Trevi's website, with a 30-day replay option available after the event.

Trevi Therapeutics (NASDAQ: TRVI) announced positive topline results from its Phase 2a RIVER trial evaluating Haduvio for refractory chronic cough (RCC). The trial met its primary endpoint with a 57% placebo-adjusted reduction in 24-hour cough frequency (p<0.0001).

Key findings include:

• 67% reduction in cough frequency from baseline
• 66% reduction in severe cough subgroup
• 68% reduction in moderate cough subgroup
• 84% of Haduvio patients achieved at least 30% reduction in cough frequency vs 29% for placebo

The trial involved 66 patients in a randomized, double-blind, placebo-controlled crossover study. Significant improvements were observed as early as Day 7 at the lowest dose (27mg BID). Common side effects included constipation, nausea, somnolence, headache, dizziness, and fatigue, with no serious adverse events reported.

Trevi Therapeutics (NASDAQ: TRVI) has scheduled a conference call and webcast for March 10th, 2025, at 8:30 a.m. ET to present topline results from their Phase 2a RIVER trial of Haduvio™. The trial evaluates oral nalbuphine ER for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

The presentation will include audio and slides, accessible via webcast. Participants can join by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international). A 30-day replay will be available on the company's website after the event.

Trevi Therapeutics (Nasdaq: TRVI), focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, has announced its participation in three major investor conferences this March.

The schedule includes:

• TD Cowen 45th Annual Health Care Conference (March 3-5) in Boston, featuring a corporate presentation on March 4 at 10:30 AM ET by CFO Lisa Delfini and CCO Farrell Simon
• Leerink Partners Global Healthcare Conference (March 10-12) in Miami, with a presentation on March 12 at 8:00 AM ET by CEO Jennifer Good and CDO James Cassella
• Leerink Partners Mountain Meeting (March 23-26) in Jackson Hole, with CFO Lisa Delfini representing

All events will feature corporate presentations available to in-person attendees.